EUVIMEDEUVIMED entdecken
LeitlinieOpen Access

Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group

Sabine Mueller iD, Jason Fangusaro, Arzu Onar Thomas, Thomas S Jacques, Pratiti Bandopadhayay iD, Peter de Blank iD, Roger J Packer, Maryam Fouladi iD, Antoinette Schouten van Meeteren, David Jones, Arie Perry, Yoshiko Nakano und 6 weitere

Neuro-Oncology · 2024

DOI: 10.1093/neuonc/noad227 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Sabine Mueller und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Neurological Surgery and Pediatrics, University of California, San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Brain Neoplasms, Glioma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Within the last few decades, we have witnessed tremendous advancements in the study of pediatric low-grade gliomas (pLGG), leading to a much-improved understanding of their molecular underpinnings. Consequently, we have achieved successful milestones in developing and implementing targeted therapeutic agents for treating these tumors. However, the community continues to face many unknowns when it comes to the most effective clinical implementation of these novel targeted inhibitors or combinations thereof. Questions encompassing optimal dosing strategies, treatment duration, methods for assessing clinical efficacy, and the identification of predictive biomarkers remain unresolved. Here, we offer the consensus of the international pLGG coalition (iPLGGc) clinical trial working group on these important topics and comment on clinical trial design and endpoint rationale. Throughout, we seek to standardize the global approach to early clinical trials (phase I and II) for pLGG, leading to more consistently interpretable results as well as enhancing the pace of novel therapy development and encouraging an increased focus on functional endpoints as well and quality of life for children faced with this disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBrain NeoplasmsGliomaAdolescentChildHumansYoung AdultConsensusQuality of LifeTreatment OutcomeClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicPractice Guidelines as Topic

Stichwörter der Autor:innen

Consensus recommendationEarly phase clinical trialLow grade glioma

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Neurology, Neurological Surgery and Pediatrics, University of California, San Francisco, San Francisco, California, USA.
  • Department of Pediatrics, University Children's Hospital, University of Zurich, Zürich, Switzerland.
  • Department of Hematology and Oncology, Children's Healthcare of Atlanta and Emory University, Atlanta, Georgia, USA.
  • Department of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • UCL Great Ormond Street Institute of Child Health and Histopathology Department, Developmental Biology and Cancer Programme, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA.

ORCID-Profile: Sabine Mueller, Pratiti Bandopadhayay, Peter de Blank, Maryam Fouladi

Zitieren

APA

Mueller, S., Fangusaro, J., Thomas, A. O., Jacques, T. S., Bandopadhayay, P., de Blank, P., Packer, R. J., Fouladi, M., van Meeteren, A. S., Jones, D., Perry, A., Nakano, Y., Hargrave, D., Riedl, D., Robison, N. J., Partanen, M., Fisher, M. J., & Witt, O. (2024). Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad227

Vancouver

Mueller S, Fangusaro J, Thomas AO, Jacques TS, Bandopadhayay P, de Blank P, et al. Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group. Neuro-Oncology. 2024. doi:10.1093/neuonc/noad227

BibTeX
@article{Mueller2024,
  author = {Mueller, Sabine and Fangusaro, Jason and Thomas, Arzu Onar and Jacques, Thomas S and Bandopadhayay, Pratiti and de Blank, Peter and Packer, Roger J and Fouladi, Maryam and van Meeteren, Antoinette Schouten and Jones, David and Perry, Arie and Nakano, Yoshiko and Hargrave, Darren and Riedl, David and Robison, Nathan J and Partanen, Marita and Fisher, Michael J and Witt, Olaf},
  title = {Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group},
  journal = {Neuro-Oncology},
  year = {2024},
  doi = {10.1093/neuonc/noad227}
}
Kostenlos starten →